Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycosis Fungoides | 6 | 2023 | 169 | 2.370 |
Why?
|
| Sezary Syndrome | 4 | 2022 | 80 | 2.170 |
Why?
|
| Skin Neoplasms | 12 | 2023 | 5860 | 1.110 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 4 | 2022 | 210 | 1.020 |
Why?
|
| Exanthema | 3 | 2024 | 502 | 0.920 |
Why?
|
| Pentoxifylline | 1 | 2023 | 53 | 0.870 |
Why?
|
| Stomatitis, Aphthous | 1 | 2023 | 51 | 0.850 |
Why?
|
| Behcet Syndrome | 1 | 2023 | 86 | 0.820 |
Why?
|
| Histiocytic Sarcoma | 1 | 2022 | 40 | 0.780 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2023 | 125 | 0.770 |
Why?
|
| Lymphoma, T-Cell | 1 | 2023 | 308 | 0.720 |
Why?
|
| Polycythemia Vera | 1 | 2022 | 160 | 0.710 |
Why?
|
| Myasthenia Gravis | 1 | 2023 | 214 | 0.710 |
Why?
|
| Drug Eruptions | 1 | 2023 | 335 | 0.710 |
Why?
|
| Myositis | 1 | 2023 | 268 | 0.700 |
Why?
|
| Lymphoma, Follicular | 1 | 2022 | 460 | 0.590 |
Why?
|
| Myocarditis | 1 | 2023 | 802 | 0.500 |
Why?
|
| Scleroderma, Localized | 2 | 2023 | 85 | 0.370 |
Why?
|
| Biological Products | 1 | 2020 | 948 | 0.370 |
Why?
|
| Alopecia Areata | 2 | 2023 | 130 | 0.350 |
Why?
|
| Lupus Erythematosus, Cutaneous | 2 | 2020 | 75 | 0.330 |
Why?
|
| Dermatology | 3 | 2024 | 905 | 0.320 |
Why?
|
| Melanoma | 3 | 2023 | 5702 | 0.280 |
Why?
|
| Immunotherapy | 3 | 2023 | 4747 | 0.270 |
Why?
|
| Oncolytic Virotherapy | 2 | 2023 | 520 | 0.260 |
Why?
|
| Skin Diseases | 2 | 2024 | 1084 | 0.240 |
Why?
|
| Psoriasis | 2 | 2023 | 925 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 7430 | 0.210 |
Why?
|
| Scleromyxedema | 1 | 2022 | 7 | 0.210 |
Why?
|
| Histiocytes | 1 | 2022 | 97 | 0.190 |
Why?
|
| Keratosis, Actinic | 1 | 2022 | 71 | 0.190 |
Why?
|
| Vitiligo | 1 | 2022 | 97 | 0.190 |
Why?
|
| Containment of Biohazards | 1 | 2020 | 39 | 0.180 |
Why?
|
| Injections, Intralesional | 1 | 2020 | 280 | 0.170 |
Why?
|
| Fasciitis | 1 | 2020 | 66 | 0.170 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2021 | 169 | 0.160 |
Why?
|
| Arthritis, Psoriatic | 1 | 2022 | 219 | 0.160 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2022 | 176 | 0.160 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2022 | 527 | 0.150 |
Why?
|
| Skin | 2 | 2023 | 4499 | 0.140 |
Why?
|
| Dermatomyositis | 1 | 2020 | 259 | 0.140 |
Why?
|
| Acne Vulgaris | 1 | 2022 | 352 | 0.140 |
Why?
|
| Oncolytic Viruses | 1 | 2020 | 344 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 878 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2022 | 2510 | 0.130 |
Why?
|
| Eosinophilia | 1 | 2020 | 554 | 0.130 |
Why?
|
| Neoplasms | 2 | 2023 | 22350 | 0.120 |
Why?
|
| Herpesvirus 1, Human | 1 | 2020 | 743 | 0.120 |
Why?
|
| Humans | 24 | 2024 | 766812 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2019 | 1497 | 0.100 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2013 | 147 | 0.100 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1791 | 0.100 |
Why?
|
| Benzoates | 1 | 2013 | 213 | 0.090 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 1814 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 1642 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 8540 | 0.090 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 4892 | 0.080 |
Why?
|
| Disease Management | 1 | 2019 | 2533 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2020 | 10101 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2022 | 65286 | 0.070 |
Why?
|
| Biopsy | 1 | 2019 | 6779 | 0.070 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 10263 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 2023 | 81657 | 0.060 |
Why?
|
| Radioimmunotherapy | 1 | 2024 | 93 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 11218 | 0.060 |
Why?
|
| DNA Damage | 1 | 2013 | 2469 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2013 | 2030 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 3723 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 9407 | 0.050 |
Why?
|
| Lip | 1 | 2022 | 196 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 5753 | 0.040 |
Why?
|
| Phenotype | 1 | 2019 | 16722 | 0.040 |
Why?
|
| Incidence | 1 | 2019 | 21527 | 0.040 |
Why?
|
| Phototherapy | 1 | 2023 | 368 | 0.040 |
Why?
|
| Histamine Antagonists | 1 | 2020 | 93 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2024 | 811 | 0.040 |
Why?
|
| Mucins | 1 | 2022 | 569 | 0.040 |
Why?
|
| Antibodies, Antinuclear | 1 | 2020 | 340 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 13489 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2020 | 702 | 0.040 |
Why?
|
| Edema | 1 | 2022 | 764 | 0.040 |
Why?
|
| Prognosis | 1 | 2019 | 29959 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2019 | 354 | 0.040 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 427 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 13644 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 2020 | 619 | 0.030 |
Why?
|
| Consensus | 1 | 2024 | 3208 | 0.030 |
Why?
|
| Antimalarials | 1 | 2020 | 909 | 0.030 |
Why?
|
| Pyrazolones | 1 | 2013 | 8 | 0.030 |
Why?
|
| Nitrobenzenes | 1 | 2013 | 64 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2023 | 2056 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 1884 | 0.020 |
Why?
|
| Quality of Life | 2 | 2023 | 13476 | 0.020 |
Why?
|
| Histone Acetyltransferases | 1 | 2013 | 333 | 0.020 |
Why?
|
| Gene Expression | 1 | 2023 | 7585 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 4652 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2022 | 4410 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 5690 | 0.020 |
Why?
|
| Middle Aged | 4 | 2022 | 223267 | 0.020 |
Why?
|
| Survival Rate | 1 | 2019 | 12826 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2013 | 2925 | 0.010 |
Why?
|
| Aged | 3 | 2020 | 171344 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 3828 | 0.010 |
Why?
|
| Male | 3 | 2020 | 364154 | 0.010 |
Why?
|
| Female | 3 | 2020 | 396532 | 0.010 |
Why?
|
| Apoptosis | 1 | 2013 | 9514 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 17089 | 0.010 |
Why?
|
| Adult | 2 | 2021 | 223305 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2019 | 54872 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 59548 | 0.010 |
Why?
|
| Child | 1 | 2022 | 80670 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 59939 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 88902 | 0.010 |
Why?
|
Concepts
(113)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(41)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_